Abstracts Archive - Page 2348 of 2607 - ACR Meeting Abstracts

Abstract Number: 1265 • 2013 ACR/ARHP Annual Meeting
Initial Benchmarking Of The Quality Of Medical Care Of Children and Adolescents With Lupus
Ahmad I. Zaal¹, Julia G. Harris², Clovis A. Silva³, Marco F. Sliva⁴, Jiha Lee⁵, Alexandria J. Greenler⁶, Simone Appenzeller⁷, Maraisa Centeville⁷, HaiMei Liu⁸, Joshua D. Pendl⁵, Jennifer L. Huggins¹, Jessica M. Sage⁶ and Hermine Brunner⁹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Children's Hospital of Wisconsin, Milwaukee, WI, ³Children's Institute, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit-Children’s Institute,, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil, ⁸Children's Hospital of Fundan University, Shanghai, China, ⁹Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Recently, 26 quality indicators (QI) for childhood-onset systemic lupus erythematous (cSLE) have been developed based on international consensus and scientific evidence. QI are defined…
Abstract Number: 1267 • 2013 ACR/ARHP Annual Meeting
Impact Of Disease Duration On Vascular Surrogates Of Early Atherosclerosis In Childhood-Onset Systemic Lupus Erythematosus
Julie Barsalou¹, Timothy J. Bradley², Cameron Slorach², Lawrence W.K. Ng³, Deborah M. Levy⁴ and Earl D. Silverman¹, ¹Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Cardiovascular disease is a leading cause of morbidity and mortality in adults with systemic lupus erythematosus. Exposure to atherogenic risk factors in childhood-onset SLE…
Abstract Number: 1268 • 2013 ACR/ARHP Annual Meeting
Long-Term Follow-Up Of a Pediatric Lupus Cohort: Transition Of Care and Health Related Outcomes
Susanna Felsenstein¹, Anusha Ramanathan², Beatriz Gonzalez³ and Andreas Reiff⁴, ¹Pediatric Infectious Diseases, Children's Hospital Los Angeles, Los Angeles, CA, ²Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ³Pediatric Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ⁴Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA
Background/Purpose: Transition from pediatric to adult care is a difficult process with the potential for negative impact on medical, psychological and social outcomes. In this…
Abstract Number: 1269 • 2013 ACR/ARHP Annual Meeting
The Development Of a Mobile Application For Adolescents and Young Adults With Lupus
Natasha M. Ruth¹, Deborah M. Levy², Andrea Regina³, Christy Taberner⁴, Edith M. Williams⁵ and Miriam Kaufman⁶, ¹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ²Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ³Department of Psychology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Mohawk College, Toronto, ON, Canada, ⁵Institute for Partnerships to Eliminate Health Disparities, University of South Carolina, Columbia, SC, ⁶Adolescent Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Young adults with lupus need reliable disease-specific knowledge that includes information about lupus, the effect of lupus and lupus medication on their lives, and…
Abstract Number: 1270 • 2013 ACR/ARHP Annual Meeting
Risk Factors For The Development Of Avascular Necrosis In Pediatric Systemic Lupus Erythematosus Patients
Reut Gurion¹, Howard Yang², Hong Li³, Stephanie Frenkian², Kathleen A. Haines⁴, Jennifer E. Weiss⁵, Yukiko Kimura⁵, Andrew S. Zeft⁶, Angela B. Robinson⁷, Suzanne C. Li⁸ and for The CARRA Registry Investigators⁹, ¹Pediatric Infectious Diseases, Rheumatology, and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, ²Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ³Case Western Reserve University, Cleveland, OH, ⁴Department of Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ⁵Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ⁶Pediatric Institute, Department of Pediatric Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ⁷Pediatric Infectious Disease, Rheumatology and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, ⁸Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ⁹Duke Clinical Research Institute, Durham, NC
Background/Purpose: Avascular necrosis (AVN) is a serious morbidity of pediatric systemic lupus erythematosus (pSLE) associated with disability, impaired quality of life, and increased cost of…
Abstract Number: 1271 • 2013 ACR/ARHP Annual Meeting
Longitudinal Disease Trajectory Of Juvenile Dermatomyositis
Lily Siok Hoon Lim^1,2, Eleanor Pullenayegum³, Dafna D. Gladman⁴, Earl D. Silverman⁵ and Brian M. Feldman⁶, ¹Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada, ³Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: 1) To determine the longitudinal disease activity trajectory of an inception cohort of Juvenile Dermatomyositis (JDM) patients, 2) To identify predictor(s) for longitudinal disease…
Abstract Number: 1272 • 2013 ACR/ARHP Annual Meeting
Whole-Body Versus Thigh Magnetic Resonance Imaging In The Assessment Of Juvenile Dermatomyositis
Clara Malattia¹, Annalisa Madeo², Marta Dellepiane³, Diliana Beleva³, Stefania Viola⁴, Alessandro Consolaro⁵, Nicolino Ruperto¹ and Alberto Martini⁶, ¹PRINTO, Genoa, Italy, ²Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy, ³Istituto G. Gaslini, Pediatria 2, Genoa, Italy, ⁴Istituto G. Gaslini, Istituto Giannina Gaslini, Genova, Italy, ⁵Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ⁶Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy, Genoa, Italy
Background/Purpose: MRI is a promising tool to assess disease activity in juvenile dermatomyositis (JDM). So far all MRI JDM studies focused on the thigh musculature.…
Abstract Number: 1273 • 2013 ACR/ARHP Annual Meeting
Granulomatosis With Polyangiitis In Children Is More Severe Than In Adults. A Long-Term, Single Center, Follow Up Study
Francesco Zulian¹, Grazia Minardo², Valeria Carraro³, Franco Schiavon³ and Giorgia Martini⁴, ¹PRINTO, Genoa, Italy, ²Department of Pediatrics, University of Padua, Padua, Italy, ³Rheumatology Clinic, University of Padova, Padova, Italy, ⁴Department of Pediatrics,, University of Padua, Padua, Italy
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a rare disease in childhood. Treatment strategies and clinical approach are still mostly derived from adult GPA studies. The…
Abstract Number: 1274 • 2013 ACR/ARHP Annual Meeting
Maternal Vitamin D, Fetal C-Reactive Protein and Brain Natriuretic Peptide Associate With The Development and Morbidity Of Cardiac Neonatal Lupus
Amit Saxena¹, Peter M. Izmirly², Joanne H. Reed³, Sara Sahl², Deborah Friedman⁴, Robert M. Clancy³ and Jill P. Buyon², ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: Women with anti-Ro antibodies face the risk of having a child with cardiac Neonatal Lupus (NL), characterized by congenital heart block and/or cardiomyopathy. Biomarkers…
Abstract Number: 1275 • 2013 ACR/ARHP Annual Meeting
Prenatal Exposure To Fluorinated Steroids Does Not Affect Long Term Morbidity In Cardiac Neonatal Lupus
Amit Saxena¹, Peter M. Izmirly², Sara Sahl², Deborah Friedman³ and Jill P. Buyon², ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: Cardiac Neonatal Lupus (NL), characterized by inflammation and fibrosis of the conduction system, endocardium, and myocardium in anti-Ro exposed fetuses, results in significant morbidity…
Abstract Number: 1244 • 2013 ACR/ARHP Annual Meeting
Low Bone Mineral Density In African-American Males May Be More Prevalent Than Previously Reported and Exhibits Association With Low BMI But Not Older Age – Results Of a Retrospective Cohort Analysis
Khush Aujla¹ and Vikas Majithia², ¹Division of Rheumatology, University of Mississippi School of Medicine, Jackson, MS, ²Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS
Background/Purpose: Osteoporosis (OP) in Males is prevalent and frequently under-recognized. There are a number of known demographic factors such as age, race and BMI as…
Abstract Number: 1235 • 2013 ACR/ARHP Annual Meeting
Predictors Of Fracture In Patients With Osteopenia: Data From An Observational Cohort
Kathryn Mitchell¹, Peter Diggle¹ and Marwan Bukhari^1,2, ¹Faculty of Health and Medicine, Lancaster, United Kingdom, ²Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: The risk factors for osteoporotic fragility fractures are well documented in the literature and although they are associated with a diagnosis of established osteoporosis…
Abstract Number: 1236 • 2013 ACR/ARHP Annual Meeting
Outcomes and Costs Of Sacral Insufficiency Fractures
Shahryar Hadavi¹, Sanam Kia¹, Christian Dejaco², Bhaskar Dasgupta² and Frances Borg³, ¹Rheumatology Department, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ³Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom
Background/Purpose: Sacral insufficiency fracture (SIF) is a poorly recognised cause of lower back pain in the elderly with significant potential morbidity. Diagnosis is often slow…
Abstract Number: 1237 • 2013 ACR/ARHP Annual Meeting
Denosumab Leads To Significantly Greater Increases In Bone Mineral Density Than Ibandronate and Risedronate In Postmenopausal Women At High Risk For Fracture Who Were Previously Treated With An Oral Bisphosphonate
Jacques P. Brown¹, Michael A. Bolognese², Pei-Ran Ho³, Jesse Hall³, Christian Roux⁴, Henry G. Bone⁵, Sydney Bonnick⁶, Joop van den Bergh⁷, Irene Ferreira⁸, Prayashi Ghelani⁹, Paula Dakin³, Rachel B. Wagman³ and Chris Recknor¹⁰, ¹CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ²Bethesda Health Research Center, Bethesda, MD, ³Amgen Inc., Thousand Oaks, CA, ⁴Paris Descartes University, Paris, France, ⁵Michigan Bone and Mineral Clinic, Detroit, MI, ⁶Clinical Research Center of North Texas, Denton, TX, ⁷VieCuri Medical Centre and Maastricht University, Venlo, Netherlands, ⁸Amgen Inc., Cambridge, United Kingdom, ⁹Ovatech Solutions, London, United Kingdom, ¹⁰United Osteoporosis Centers, Gainesville, GA
Denosumab Leads to Significantly Greater Increases in Bone Mineral Density Than Ibandronate and Risedronate in Postmenopausal Women at High Risk for Fracture Who Were Previously…
Abstract Number: 1238 • 2013 ACR/ARHP Annual Meeting
Persistence At 12 Months With Denosumab (Prolia^®) In Postmenopausal Women With Osteoporosis: Interim Results From a Prospective Observational Study
Stuart L. Silverman¹, Ethel Siris², David L. Kendler³, Dea Belazi⁴, Jacques P. Brown⁵, Deborah T. Gold⁶, E. Michael Lewiecki^7,8, Alexandra Papaioannou⁹, Christine Simonelli¹⁰, Irene Ferreira¹¹, Paula Dakin¹², Suresh Siddhanti¹², Bradley Stolshek¹² and Christopher Recknor¹³, ¹Cedars-Sinai Medical Center, UCLA Center of Excellence, Los Angeles, CA, ²Columbia University, New York, NY, ³University of British Columbia, Vancouver, BC, Canada, ⁴AlchemiPharma LLC, Wayne, PA, ⁵CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ⁶Duke University Medical Center, Durham, NC, ⁷University of New Mexico School of Medicine, Albuquerque, NM, ⁸New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁹Geriatric Medicine, McMaster University, Hamilton, ON, Canada, ¹⁰Health East Osteoporosis Care, Woodbury, MN, ¹¹Amgen Inc., Cambridge, United Kingdom, ¹²Amgen Inc., Thousand Oaks, CA, ¹³United Osteoporosis Centers, Gainesville, GA
Background/Purpose: Persistence with osteoporosis therapy is important for optimal reduction of fracture risk. Persistence with denosumab was >90% in a randomized clinical trial in women…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].